



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am on Wednesday 14th September 2022
at The All Nations Centre, Sachville Avenue, Cardiff, CF14 3NY**

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0922

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Full Submission (WPAS)**
Hydrocortisone MR (Efmody®) for treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults 2/AWMSG/0922
Appendices
6. **Appraisal 2: Paediatric Licence Extension (PAS)**
Dupilumab (Dupixent®) indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment 3/AWMSG/0922
Appendices

The meeting will now open to the public for the committee decisions

7. **Chairman's report (verbal update)**
8. **Appraisal 3: Directed (full assessment)**
Rituximab (MabThera®) for treatment of patients with moderate to severe pemphigus vulgaris 4/AWMSG/0922
Appendices
9. **Appraisal 4: Paediatric Licence Extension (PLE)**
Iacosamide (Vimpat®) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 2 years of age ≤ 4 years of age with epilepsy 5/AWMSG/0922
Appendices

10.	Appraisal 5: Paediatric Licence Extension Insulin degludec (Tresiba®) for treatment of diabetes mellitus in adolescents and children from the age of 1 year	6/AWMSG/0922 Appendices
11.	AWTTC work programme consultation – for information	7/AWMSG/0922
	SBAR: Frequency of NPI review and update – proposal for AWMSG endorsement	8/AWMSG/0922
12.	All Wales Guidance for Prescribing intervals – for endorsement	9/AWMSG/0922
13.	Value-based prescribing – Biological medicines for severe uncontrolled asthma – for endorsement	10/AWMSG/0922 Appendix
14.	Value-based prescribing – Low value for prescribing review – for endorsement	11/AWMSG/0922
15.	All Wales Chronic Pain Resources – for endorsement	12/AWMSG/0922
16.	Antibiotic Review Kit (ARK) hospital in-patient medication chart – for acknowledgement	13/AWMSG/0922
17.	Daptomycin prescribing and monitoring guideline – for acknowledgement	14/AWMSG/0922
18.	Colistimethate sodium prescribing and monitoring guideline in adults – for acknowledgement	15/AWMSG/0922
19.	Teicoplanin prescribing and monitoring guideline for adults – for acknowledgement	16/AWMSG/0922
20.	Antimicrobial dosing in extremes of body weight in adults – for acknowledgement	17/AWMSG/0922
21.	Antimicrobial dosing in adults with renal impairment – for acknowledgement	18/AWMSG/0922
22.	Primary care antimicrobial guidelines (updates) – for information	19/AWMSG/0922
23.	CEPP National Audit - Focus on Antibiotic Prescribing (updates) – for information	20/AWMSG/0922
24.	Management of Recurrent Symptomatic Urinary Tract Infection in Adult Women (updates) – for information	21/AWMSG/0922
25.	National Prescribing Indicators 2021-22: Analysis of prescribing data to Mar 22 – for information	22/AWMSG/0922

26. Any other business

Date of next meeting – Tuesday 11th October 2022